Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phoenix study: nal-IRI plus S-1 in metastatic or recurrent pancreatic cancer after gemcitabine
jRCTs031210040Phase 2Completed
- Sponsor
- Nihon Servier
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan and tegafur in pancreatic adenocarcinoma (PDAC), sponsored by Nihon Servier. Started May 2021; status: completed.
02
Drugs
irinotecantegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCTs031210040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210040.